1.Kumar, Sudeep, Raju Sunagar, and Edmund J. Gosselin (2019).“Bacterial Protein Toll-Like-Receptor Agonists: A Novel Perspective on Vaccine Adjuvants.” Frontiers in immunology 10 (2019): 1144.
2. GAO (U.S.GOVERNMENT ACCOUNTABILITY OFFICE). Analysis of GAO-20-215SP, FDA, HHS, and pharmaceutical research and manufactures of America (PhRMA)documentation, GAO20-583SP, SCIENCE & TECH SPOTLIGHT:
COVID-19 Vaccine Development, Published: May 26, 2020.
3. Candanosa, R.M. (2020) .Here’s how nanoparticles could help us get closer to a treatment for COVID-19.
https://news.northeastern.edu/2020/03/04/heres-how-nanoparticles-could-help-us-get-closer-to-a-treatment-for-covid-19/ (Accessed: 07 September2020).https://www.labnews.co.uk/article/2030847/fast tracking nano vaccines-to-fight-coronavirus.
4. Xia S, Duan K, Zhang Y, et al. (2020). Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA 2020; 324: 1–10.
5.Xia S, Zhang Y, Wang Y, et al. (2020 ).Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2020; published online Oct 15. https://doi.org/10.1016/S1473-3099(20)30831
7. Clinical Trials (2020) Pfizer and BioNTech report positive data of second Covid-19 vaccine [online].
Availableat:https://www.clinicaltrialsarena.com/news/pfizer-biontech-second-vaccine-2/ (Accessed: 06 September 2020)
8. Clinical trial government (2020). History of Changes for Study: (NCT04283461).Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19).https://clinicaltrials.gov/ct2/history/NCT04283461.
9. Sheahan, T.P.; Sims, A.C.; Leist, S.R.; Schäfer, A.; Won, J.; Brown, A.J.; Montgomery, S.A.; Hogg, A.; Babusis, D.; Clarke, M.O.; et al.(2020) Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. 2020, 11, 1–14.
10. Lee, J.-W.; Gupta, N.; Serikov, V.; Matthay, M.A.(2009) Potential application of mesenchymal stem cells in acute lung injury. Expert Opin. Boil. 2009, 9, 1259–127.
14. Agostini, M.L.; Andres, E.L.; Sims, A.C.; Graham, R.L.; Sheahan, T.P.; Lu, X.; Smith, E.C.; Case, J.B.; Feng, J.Y.; Jordan, R.; et al.(2018) Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio 2018, 9.
15. Chappell, K.; Watterson, D.; Young, P.(2018). Rapid response pipeline for stabilized subunit vaccines. In Proceedings of the Vaccine Technology VII, Mont Tremblant, QC, Canada, 17–22 June 2018.
16. Bhardwaj, P. and Bhatia, E., et.al, (2020).Advancements in prophylactic and therapeutic nano vaccines. Acta Biomaterilia,108,1-21,2020.
18.Le, Tung T., Zacharias Andreadakis, Arun Kumar, Raúl G. Román, Stig Tollefsen, Melanie Saville, and Stephen Mayhew (2020). “The COVID-19 vaccine development landscape.” Nature Reviews Drug Discovery, vol. 19 (2020): pp. 305-306.